We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inhibrx (INBX) Down on Updated Data From Bone Cancer Study
Read MoreHide Full Article
Inhibrx (INBX - Free Report) reported updated safety and efficacy data from ongoing expansion cohorts of a phase I study evaluating INBRX-109 for chondrosarcoma.
Shares of Inhibrx were down 11.52% on Nov 17 in response to the news, possibly because the benefit of the study observed was less than the investors’ expectations.
Image Source: Zacks Investment Research
The stock has fallen 33.1% year to date compared with the industry’s decline of 17.9%.
Chondrosarcoma is a rare type of malignant bone cancer, primarily occurring in adults. Per the company, the disease — with an annual incidence of 1 in 2000,000 — currently has no approved therapies.
INBRX-109 is a tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation.
The company presented the dataset updated till May 2022 at the Annual Connective Tissue Oncology Society (CTOS) Conference on Nov 16. The dataset included matured data on the original cohort of chondrosarcoma patients and initial data from an additional cohort of chondrosarcoma patients with the isocitrate dehydrogenase (IDH) mutation. The company also announced additional updated data from the present dataset updated as of November 2022.
The study exhibited an 87.9% disease control rate in the subjects, as measured by RECISTv1.1. 6.1% of the subjects achieved partial responses in the study.
81.8% of the patients achieved stable disease, out of which 55.6% witnessed a decline in tumor size from the baseline. Disease control was observed in patients with and without IDH1/IDH2 mutations.
The clinical benefit of the candidate was durable. Of the subjects who achieved disease control, 42.4% had a clinical benefit lasting more than six months. The longest duration of stable disease under treatment with INBRX-109 was 20 months.
The median progression-free survival (PFS) in the subjects in 7.6 months.
Treatment-related adverse events (AEs) were less than 5% among the subjects.
The candidate has also received a Fast-Track designation from the FDA in 2021 for treating unresectable or metastatic conventional chondrosarcoma.
Immunocore’s loss per share estimates for 2022 have narrowed from $1.25 to 97 cents in the past 30 days. The loss per share for 2023 has narrowed from $1.69 to $1.10 in the same time frame.
Earnings of Immunocore beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. The average earnings surprise for IMCR is 68.34%.
AVEO Pharmaceuticals loss per share estimates for 2022 have narrowed down from 94 cents to 68 cents over the past 30 days. The earnings estimate for 2023 have remained steady at improved from 41 cents to 52 cents in the same time frame.
Earnings of AVEO beat estimates in three of the trailing four quarters, while missing the same in the reaming occasion. The average earnings surprise for AVEO is 19.87%.
Eton Pharmaceuticals’ loss per share estimates for 2022 have remained steady at 44 cents in the past 30 days. The earnings per share for 2023 have remained steady at a cent in the same time frame.
Earnings of Eton missed estimates in three of the trailing four quarters, while beating the same on the remaining occasion. The average earnings surprise for ETON is 115.63%.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Inhibrx (INBX) Down on Updated Data From Bone Cancer Study
Inhibrx (INBX - Free Report) reported updated safety and efficacy data from ongoing expansion cohorts of a phase I study evaluating INBRX-109 for chondrosarcoma.
Shares of Inhibrx were down 11.52% on Nov 17 in response to the news, possibly because the benefit of the study observed was less than the investors’ expectations.
Image Source: Zacks Investment Research
The stock has fallen 33.1% year to date compared with the industry’s decline of 17.9%.
Chondrosarcoma is a rare type of malignant bone cancer, primarily occurring in adults. Per the company, the disease — with an annual incidence of 1 in 2000,000 — currently has no approved therapies.
INBRX-109 is a tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation.
The company presented the dataset updated till May 2022 at the Annual Connective Tissue Oncology Society (CTOS) Conference on Nov 16. The dataset included matured data on the original cohort of chondrosarcoma patients and initial data from an additional cohort of chondrosarcoma patients with the isocitrate dehydrogenase (IDH) mutation. The company also announced additional updated data from the present dataset updated as of November 2022.
The study exhibited an 87.9% disease control rate in the subjects, as measured by RECISTv1.1. 6.1% of the subjects achieved partial responses in the study.
81.8% of the patients achieved stable disease, out of which 55.6% witnessed a decline in tumor size from the baseline. Disease control was observed in patients with and without IDH1/IDH2 mutations.
The clinical benefit of the candidate was durable. Of the subjects who achieved disease control, 42.4% had a clinical benefit lasting more than six months. The longest duration of stable disease under treatment with INBRX-109 was 20 months.
The median progression-free survival (PFS) in the subjects in 7.6 months.
Treatment-related adverse events (AEs) were less than 5% among the subjects.
The candidate has also received a Fast-Track designation from the FDA in 2021 for treating unresectable or metastatic conventional chondrosarcoma.
Inhibrx, Inc. Price
Inhibrx, Inc. price | Inhibrx, Inc. Quote
Zacks Rank and Stocks to Consider
Inhibrx currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector are Immunocore (IMCR - Free Report) , carrying a Zacks Rank #1 (Strong Buy) and AVEO Pharmaceuticals and Eton Pharmaceuticals (ETON - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Immunocore’s loss per share estimates for 2022 have narrowed from $1.25 to 97 cents in the past 30 days. The loss per share for 2023 has narrowed from $1.69 to $1.10 in the same time frame.
Earnings of Immunocore beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. The average earnings surprise for IMCR is 68.34%.
AVEO Pharmaceuticals loss per share estimates for 2022 have narrowed down from 94 cents to 68 cents over the past 30 days. The earnings estimate for 2023 have remained steady at improved from 41 cents to 52 cents in the same time frame.
Earnings of AVEO beat estimates in three of the trailing four quarters, while missing the same in the reaming occasion. The average earnings surprise for AVEO is 19.87%.
Eton Pharmaceuticals’ loss per share estimates for 2022 have remained steady at 44 cents in the past 30 days. The earnings per share for 2023 have remained steady at a cent in the same time frame.
Earnings of Eton missed estimates in three of the trailing four quarters, while beating the same on the remaining occasion. The average earnings surprise for ETON is 115.63%.